Alembic Ltd
NSE: ALEMBICLTD BSE: 506235
₹91.72
(0.64%)
Tue, 03 Mar 2026, 07:47 pm
Market Cap23.51B
PE Ratio7.39
Dividend2.62
Health Technology
Pharmaceuticals: Major
24.5KAlembic Analysis
dividend
- Dividends per share have increased over the past 10 years.
- Dividends paid are thoroughly covered by earnings (21.4x coverage).
- Dividends per share have been volatile in the past 10 years (annual drop of over 20%).
- Alembic's pays a lower dividend yield than the bottom 25% of dividend payers in India (0.76%).
- Alembic's dividend is below the markets top 25% of dividend payers in India (3.08%).
health
- Alembic is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
- Alembic is profitable, therefore cash runway is not a concern.
- Alembic is profitable, therefore cash runway is not a concern.
- Alembic has no debt, it does not need to be covered by operating cash flow.
- Alembic has no debt, it does not need to be covered by short term assets.
- Alembic's cash and other short term assets cover its long term commitments.
- Alembic currently has no debt however we can't compare to 5 years ago as we have no data for that period.
- Alembic has no debt, therefore coverage of interest payments is not a concern.
- Alembic has no debt.
- Low level of unsold assets.
management
- The tenure for the Alembic board of directors is about average.
- Malika's remuneration is lower than average for companies of similar size in India.
- Malika's compensation has been consistent with company performance over the past year, both up more than 20%.
- The average tenure for the Alembic management team is over 5 years, this suggests they are a seasoned and experienced team.
misc
- Alembic is not covered by any analysts.
- Alembic has significant price volatility in the past 3 months.
past
- Alembic's 1-year earnings growth exceeds its 5-year average (54.3% vs 26.1%)
- Alembic has delivered over 20% year on year earnings growth in the past 5 years.
- Alembic used its assets more efficiently than the IN Pharmaceuticals industry average last year based on Return on Assets.
- Alembic has efficiently used shareholders’ funds last year (Return on Equity greater than 20%).
- Alembic's earnings growth has exceeded the IN Pharmaceuticals industry average in the past year (54.3% vs 22.7%).
- Alembic's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
value
- Alembic is good value based on assets compared to the IN Pharmaceuticals industry average.
- Alembic is good value based on earnings compared to the IN Pharmaceuticals industry average.
- Alembic is good value based on earnings compared to the India market.
- 506235 outperformed the Pharmaceuticals industry which returned 26.7% over the past year.
- 506235 outperformed the Market in India which returned -14.5% over the past year.
- BSE:506235 is up 49.9% outperforming the Pharmaceuticals industry which returned 6.8% over the past month.
- BSE:506235 is up 49.9% outperforming the market in India which returned 8% over the past month.
- Alembic's share price is above the future cash flow value, it's not available at a moderate discount (< 20%).
- Alembic's share price is above the future cash flow value, it's not available at a substantial discount (< 40%).
Open Your Free Demat Account Now!
Facebook
Twitter
Instagram
LinkedIn
Youtube
Calculators
Popular Calculators
Group Stocks
Pocketful Fintech Capital Private Limited (CIN U65999DL2021PTC390548) | The SEBI Registration No. allotted to us is INZ000313732. NSE Member Code: 90326 | BSE Member Code: 6808 | MCX Member Code: 57120 DP | CDSL: 12099800